Literature DB >> 9230634

Gender, estrogen, and schizophrenia.

L A Lindamer1, J B Lohr, M J Harris, D V Jeste.   

Abstract

Most of the evidence to support an association between estrogen and psychosis is indirect and comes from clinical studies of gender differences in schizophrenia and from studies of fluctuating levels of psychopathology in different phases of the menstrual cycle. Our data, as well as those of other investigators, suggest a significantly later age at onset of schizophrenia in women than in men. There is somewhat more direct evidence from animal studies indicating that estrogen modulates dopamine systems in a manner similar to neuroleptics, although there are some inconsistencies in the literature. Few studies have examined the effects of estrogen administration in conjunction with neuroleptics on psychotic symptoms. We present a case report of a postmenopausal women with schizophrenia who had an improvement in positive symptoms with estrogen replacement therapy. Long-term double-blind treatment studies are needed to investigate the effects of estrogen on psychotic symptoms in women with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230634

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  14 in total

Review 1.  Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Authors:  Michel Cyr; Frederic Calon; Marc Morissette; Thérèse Di Paolo
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

2.  COMT genotype, gender and cognition in community-dwelling, older adults.

Authors:  Ruth O'Hara; Elana Miller; Chun-Ping Liao; Nate Way; Xiaoyan Lin; Joachim Hallmayer
Journal:  Neurosci Lett       Date:  2006-10-09       Impact factor: 3.046

3.  Association Between Age at Onset of Schizophrenia and Age at Menarche.

Authors:  Esin Evren Kiliçaslan; Almila Erol; Burçak Zengin; Pınar Çetinay Aydin; Levent Mete
Journal:  Noro Psikiyatr Ars       Date:  2014-09-01       Impact factor: 1.339

4.  Predictors of current functioning and functional decline in schizophrenia.

Authors:  Jamie Joseph; William S Kremen; Carol E Franz; Stephen J Glatt; Joyce van de Leemput; Sharon D Chandler; Ming T Tsuang; Elizabeth W Twamley
Journal:  Schizophr Res       Date:  2017-01-28       Impact factor: 4.939

Review 5.  Sex steroids and schizophrenia.

Authors:  Julie A Markham
Journal:  Rev Endocr Metab Disord       Date:  2012-09       Impact factor: 6.514

6.  Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-03-17       Impact factor: 7.853

7.  A comparative profile analysis of neuropsychological function in men and women with schizotypal personality disorder.

Authors:  Martina M Voglmaier; Larry J Seidman; Margaret A Niznikiewicz; Chandlee C Dickey; Martha E Shenton; Robert W McCarley
Journal:  Schizophr Res       Date:  2005-04-01       Impact factor: 4.939

8.  Predictors of outcome in brief cognitive behavior therapy for schizophrenia.

Authors:  Alison Brabban; Sara Tai; Douglas Turkington
Journal:  Schizophr Bull       Date:  2009-07-01       Impact factor: 9.306

9.  Nuclear Receptors and Neuroinflammation in Schizophrenia.

Authors:  Shan-Yuan Tsai; Vibeke S Catts; Janice M Fullerton; Susan M Corley; Stuart G Fillman; Cynthia Shannon Weickert
Journal:  Mol Neuropsychiatry       Date:  2018-01-16

10.  Association of estrogen receptor alpha gene polymorphism with age at onset, general psychopathology symptoms, and therapeutic effect of schizophrenia.

Authors:  Shuai Wang; Wenqiang Li; Jingyuan Zhao; Hongxing Zhang; Yongfeng Yang; Xiujuan Wang; Ge Yang; Luxian Lv
Journal:  Behav Brain Funct       Date:  2013-03-15       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.